Novartis reported 3.59B in Selling and Administration Expenses for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Selling And Administration Expenses Change
Abbvie ABBV:US $ 3.13B 73M
Alcon AG ALC:SW 773.47M 39.47M
Amgen AMGN:US $ 1.33B 99M
AstraZeneca AZN:LN 3.27B 209M
Bayer BAYN:GR 4.47B 527M
Biogen BIIB:US $ 572.6M 62.3M
Bristol Myers Squibb BMY:US $ 1.78B 46M
Eli Lilly And LLY:US $ 1.63B 67.2M
Fresenius FRE:GR 1.63B 154M
Fresenius Medical Care FME:GR 969M 97.76M
Galapagos GLPG:NA 71.67M 9.33M
Genmab GEN:DC 633M 181M
Gilead Sciences GILD:US $ 1.36B 274M
GlaxoSmithKline GSK:LN 1.96B 726M
Hikma Pharmaceutical HIK:LN 256M 0
Johnson & Johnson JNJ:US $ 6.23B 288M
Merck MRK:GR 1.52B 151M
Merk MRK:US $ 2.42B 118M
Novartis NOVN:VX 3.59B 91M
Novartis NVS:US 3.59B 91M
Orion ORNBV:FH 64.7M 3.4M
Pfizer PFE:US $ 3.2B 506M
Philips PHIA:NA 1.26B 38M
Recordati REC:IM 145.08M 23.35M
Regeneron Pharmaceuticals REGN:US $ 476.3M 26.3M